Patents Examined by David K O'Dell
  • Patent number: 10766893
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: September 8, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mikkel Jessing, Morten Langgård, Paulo Jorge Vieira Vital, Jan Kehler, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson, Mauro Marigo
  • Patent number: 10759793
    Abstract: New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: September 1, 2020
    Assignee: Almirall, S.A.
    Inventors: Cristina Esteve Trias, Joan Taltavull Moll, Jacob Gonzalez Rodriguez, Bernat Vidal Juan
  • Patent number: 10759790
    Abstract: A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a therapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: September 1, 2020
    Assignee: Ichan School of Medicine at Mount Sinai
    Inventors: Michael Ohlmeyer, Nilesh Zaware
  • Patent number: 10745419
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 18, 2020
    Assignees: Loxo Oncology Inc., Array Biopharma Inc.
    Inventors: Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
  • Patent number: 10738045
    Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: August 11, 2020
    Assignee: Syngenta Participations AG
    Inventors: Pierre Joseph Marcel Jung, Andrew Edmunds, Michel Muehlebach, Roger Graham Hall
  • Patent number: 10731159
    Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: August 4, 2020
    Inventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
  • Patent number: 10730875
    Abstract: Provided herein are substituted imidazo[1,2-a]pyridin-2-ylamine compounds, for example, of formula (A), and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a Janus kinase-mediated disease.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: August 4, 2020
    Assignee: JN Therapeutics
    Inventors: Jin Li, Shung Wu, Minmin Yang, Sean Chen, Wenshan Hao
  • Patent number: 10717737
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: July 21, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Wenqing Yao, Fenglei Zhang
  • Patent number: 10717732
    Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 21, 2020
    Inventors: Yingjun Zhang, Qingyun Ren, Changhua Tang, Xiaohong Lin, Junjun Yin, Kai Yi
  • Patent number: 10688112
    Abstract: This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substitutents are disclosed herein.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 23, 2020
    Assignee: Emory University
    Inventors: Dennis Liotta, Kyle Giesler
  • Patent number: 10689378
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 23, 2020
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xingnian Fu, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • Patent number: 10689390
    Abstract: The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 23, 2020
    Inventors: Saravanan Vadivelu, Sridharan Rajagopal, Murugan Chinnapattu, Pavan Kumar Gondrala, Dhanalakshmi Sivanandhan, Chandrika Mulakala
  • Patent number: 10683291
    Abstract: Described herein are heterocyclic compounds, compositions, and methods for their use for the treatment of disease.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 16, 2020
    Inventors: Raju Mohan, John Nuss, Jason Harris
  • Patent number: 10676457
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: June 9, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Wenqing Yao
  • Patent number: 10654845
    Abstract: The invention relates to novel compounds of the formula (I) in which the R1, R2a, R2b, R3, A1, A2, A4 and n have the meanings given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: May 19, 2020
    Inventors: Ruediger Fischer, David Wilcke, Kerstin Ilg, Daniela Portz, Ulrich Goergens, Sascha Eilmus, Olga Malsam, Andreas Turberg, Sebastian Horstmann
  • Patent number: 10654865
    Abstract: Enantioselective syntheses of cis- and trans-bicyclic dihydropyran compounds, and other intermediates, en route to heteroyohimbine alkaloids.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: May 19, 2020
    Inventors: Karl A. Scheidt, Ashkaan Younai, Bi-Shun Zeng, Herbert Y. Meltzer
  • Patent number: 10654828
    Abstract: The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: May 19, 2020
    Assignee: NOVARTIS AG
    Inventors: John Ryan Kerrigan, Natalie Dales, George Scott Tria, Daniel Palacios, Paul Gormisky
  • Patent number: 10647674
    Abstract: The present invention relates to novel processes for the preparation of substituted pyridyl-methylbenzamide derivatives of formula (I), in particular 2,6-dichloro-N-{[3-chloro-5-(trifluoromethyl)-2-pyridyl]methyl}benzamide (Fluopicolide), and for the catalytic hydrogenation of substituted cyanopyridine derivatives, in particular 3-chloro-2-cyano-5-trifluoromethylpyridine [=Py-CN] to the corresponding substituted 2-methylaminopyridine derivatives, in particular 2-aminomethyl-3-chloro-5-trifluoromethylpyridine [=Py-methylamine] or salts thereof in the presence of metal catalysts such as in particular palladium catalysts, catalytic modifiers and acids.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: May 12, 2020
    Inventors: Wahed Ahmed Moradi, Günter Schlegel, Albert Schnatterer, Frank Volz
  • Patent number: 10640484
    Abstract: A method for producing (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione, the method comprising, (a) a step for isolating an isomer represented by formula (2) from a mixture of isomers represented by formula (1), and (b) a step for obtaining (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione by removing the menthyloxycarbonyl group from the compound represented by formula (2), which was isolated in step (a).
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: May 5, 2020
    Inventors: Yoshitake Sumikawa, Noriyuki Kamei, Shingo Todo
  • Patent number: 10624882
    Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: April 21, 2020
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Todd Bosanac, John David Ginn, Eugene Richard Hickey, Thomas Martin Kirrane, Jr., Weimin Liu, Anthony S. Prokopowicz, Sabine K. Schlyer, Cheng-Kon Shih, Roger John Snow, Michael Robert Turner, Frank Wu, Erick Richard Young